Global Tyrosine Kinase Inhibitors Market 2019-2023 - Product Image

Global Tyrosine Kinase Inhibitors Market 2019-2023

  • ID: 4722141
  • Report
  • Region: Global
  • 115 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • MORE
Strategic alliances to trend in the market. The growing prevalence of various diseases increases the demand for innovative therapeutics. TKI therapeutics are one of the most reliable therapeutic options for the treatment of cancer and age-related diseases such as RVO. The analysts have predicted that the tyrosine kinase inhibitors market will register a CAGR of more than 8% by 2023.

Market Overview

Recent approvals of TKIs

Many TKI therapeutic candidates are gaining approval due to their high safety profile and efficacy. The therapeutics that are in last stage of development are expected to get marketing approval during forecast period.

Side effects of TKIs

Despite highly efficacious, TKIs are associated with a spectrum of side effects such as fatigue, muscle cramps, nausea, vomiting, and diarrhea.

For the detailed list of factors that will drive and challenge the growth of the tyrosine kinase inhibitors market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer, the competitive environment is quite intense. Factors such as the rising strategic alliances and the recent approvals of TKIs, will provide considerable growth opportunities to tyrosine kinase inhibitors manufactures. Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, Novartis, and Pfizer are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • The threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • RTKIs - Market size and forecast 2018-2023
  • nRTKIs - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Novartis
  • Pfizer
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: RTKIs - Market size and forecast 2018-2023 ($ billions)
Exhibit 20: RTKIs - Year-over-year growth 2019-2023 (%)
Exhibit 21: nRTKIs - Market size and forecast 2018-2023 ($ billions)
Exhibit 22: nRTKIs - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas - Market size and forecast 2018-2023 ($ billions)
Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 19: Top 3 countries in Americas
Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ billions)
Exhibit 31: Example of patient-assistance program for cancer treatment
Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC - Market size and forecast 2018-2023 ($ billions)
Exhibit 35: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Reported top 5 new cases of cancer types in US in 2015
Exhibit 41: Treatment costs of TKIs
Exhibit 42: Side effects of TKIs
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Bristol-Myers Squibb - Vendor overview
Exhibit 53: Bristol-Myers Squibb - Business segments
Exhibit 54: Bristol-Myers Squibb - Organizational developments
Exhibit 55: Bristol-Myers Squibb - Geographic focus
Exhibit 56: Bristol-Myers Squibb - Key offerings
Exhibit 57: Bristol-Myers Squibb - Key customers
Exhibit 58: F. Hoffmann-La Roche - Vendor overview
Exhibit 59: F. Hoffmann-La Roche - Business segments
Exhibit 60: F. Hoffmann-La Roche - Organizational developments
Exhibit 61: F. Hoffmann-La Roche - Geographic focus
Exhibit 62: F. Hoffmann-La Roche - Segment focus
Exhibit 63: F. Hoffmann-La Roche - Key offerings
Exhibit 64: F. Hoffmann-La Roche - Key customers
Exhibit 65: Johnson & Johnson - Vendor overview
Exhibit 66: Johnson & Johnson - Business segments
Exhibit 67: Johnson & Johnson - Organizational developments
Exhibit 68: Johnson & Johnson - Geographic focus
Exhibit 69: Johnson & Johnson - Segment focus
Exhibit 70: Johnson & Johnson - Key offerings
Exhibit 71: Johnson & Johnson - Key customers
Exhibit 72: Novartis - Vendor overview
Exhibit 73: Novartis - Business segments
Exhibit 74: Novartis - Organizational developments
Exhibit 75: Novartis - Geographic focus
Exhibit 76: Novartis - Segment focus
Exhibit 77: Novartis - Key offerings
Exhibit 78: Novartis - Key customers
Exhibit 79: Pfizer - Vendor overview
Exhibit 80: Pfizer - Business segments
Exhibit 81: Pfizer - Organizational developments
Exhibit 82: Pfizer - Geographic focus
Exhibit 83: Pfizer - Segment focus
Exhibit 84: Pfizer - Key offerings
Exhibit 85: Pfizer - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: List of abbreviations
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • MORE
Global Tyrosine Kinase Inhibitors Market 2019-2023

The analyst recognizes the following companies as the key players in the global tyrosine kinase inhibitors market: Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, Novartis, and Pfizer.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rising strategic alliances.”

According to the report, one of the major drivers for this market is the recent approvals of TKIs.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of TKIs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Novartis
  • Pfizer
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4722141
Adroll
adroll